{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:07:56Z","timestamp":1773299276824,"version":"3.50.1"},"reference-count":11,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>It has been reported that patients with \u201cchronic Lyme disease\u201d have a decreased number of natural killer cells, as defined by the CD57 marker. We performed immunophenotyping in 9 individuals with post-Lyme disease syndrome, 12 who recovered from Lyme disease, and 9 healthy volunteers. The number of natural killer cells was not significantly different between the groups.<\/jats:p>","DOI":"10.1128\/cvi.00167-09","type":"journal-article","created":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T01:46:10Z","timestamp":1244684770000},"page":"1249-1250","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":52,"title":["Natural Killer Cell Counts Are Not Different between Patients with Post-Lyme Disease Syndrome and Controls"],"prefix":"10.1128","volume":"16","author":[{"given":"Adriana","family":"Marques","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Immunology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Fleisher","sequence":"additional","affiliation":[{"name":"Immunology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"1","volume":"57","year":"2008","unstructured":"Bacon, R., K. Kugeler, and P. Mead. 2008. Surveillance for Lyme disease\u2014United States, 1992-2006. MMWR Morb. Mortal. Wkly. Rep.57:1-9.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_3_2","first-page":"1","volume":"46","year":"1997","unstructured":"Centers for Disease Control and Prevention. 1997. Case definitions for infectious conditions under public health surveillance. MMWR Morb. Mortal. Wkly. Rep.46:1-55.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_4_2","first-page":"590","volume":"44","year":"1995","unstructured":"Centers for Disease Control and Prevention. 1995. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb. Mortal. Wkly. Rep.44:590-591.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1189\/jlb.0208107","volume":"85","year":"2009","unstructured":"Chattopadhyay, P. K., M. R. Betts, D. A. Price, E. Gostick, H. Horton, M. Roederer, and S. C. De Rosa. 2009. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J. Leukoc. Biol.85:88-97.","journal-title":"J. Leukoc. Biol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMra072023","volume":"357","year":"2007","unstructured":"Feder, H. M., Jr., B. J. Johnson, S. O'Connell, E. D. Shapiro, A. C. Steere, and G. P. Wormser. 2007. A critical appraisal of \u201cchronic Lyme disease.\u201d N. Engl. J. Med.357:1422-1430.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2007.12.011","volume":"22","year":"2008","unstructured":"Marques, A. 2008. Chronic Lyme disease: a review. Infect. Dis. Clin. North Am.22:341-360.","journal-title":"Infect. Dis. Clin. North Am."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00508-006-0687-x","volume":"118","year":"2006","unstructured":"Steere, A. C. 2006. Lyme borreliosis in 2005, 30 years after initial observations in Lyme, Connecticut. Wien. Klin. Wochenschr.118:625-633.","journal-title":"Wien. Klin. Wochenschr."},{"key":"e_1_3_2_9_2","first-page":"111","volume":"9","year":"2002","unstructured":"Stricker, R. B., J. Burrascano, and E. Winger. 2002. Longterm decrease in the CD57 lymphocyte subset in a patient with chronic Lyme disease. Ann. Agric. Environ. Med.9:111-113.","journal-title":"Ann. Agric. Environ. Med."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0165-2478(00)00316-3","volume":"76","year":"2001","unstructured":"Stricker, R. B., and E. E. Winger. 2001. Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. Immunol. Lett.76:43-48.","journal-title":"Immunol. Lett."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.SMJ.0000053458.21691.2E","volume":"96","year":"2003","unstructured":"Stricker, R. B., and E. E. Winger. 2003. Musical hallucinations in patients with Lyme disease. South. Med. J.96:711-715.","journal-title":"South. Med. J."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","volume":"43","year":"2006","unstructured":"Wormser, G. P., R. J. Dattwyler, E. D. Shapiro, J. J. Halperin, A. C. Steere, M. S. Klempner, P. J. Krause, J. S. Bakken, F. Strle, G. Stanek, L. Bockenstedt, D. Fish, J. S. Dumler, and R. B. Nadelman. 2006. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis.43:1089-1134.","journal-title":"Clin. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00167-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00167-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T16:57:58Z","timestamp":1685033878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00167-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1128\/CVI.00167-09"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00167-09","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"2009-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-06-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}